Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Helicobacter pylori is one of the most common gastric pathogens, affecting at least half the world's population, and is strongly associated with gastritis, peptic ulcer, gastric adenocarcinoma, and lymphoma. We aimed to assess the efficacy, safety, and immunogenicity of a three-dose oral recombinant H pylori vaccine in children in China.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Oct 10 2015

Volume: 386

Issue: 10002

Affiliations

[1 ] National Institute for Food and Drug Control, Beijing, China.

[2 ] College of Pharmacy, Third Military Medical University, Chongqing, China.

[3 ] Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China.

[4 ] Kangwei Biological Technology, Chongqing, China.

[5 ] Ganyu County Center for Disease Control and Prevention, Lianyungang, Jiangsu Province, China.

[6 ] Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China. Electronic address: jszfc@vip.sina.com.

[7 ] College of Pharmacy, Third Military Medical University, Chongqing, China. Electronic address: qmzou2007@163.com.

Article

Publisher Item ID: S0140-6736(15)60310-5

DOI: 10.1016/S0140-6736(15)60310-5

PubMed ID: 26142048

SO-VID: 662f0b1b-c7af-4ca9-b847-647c2ac33f34

History

Data availability:

Comments

Comment on this article

scite_

Cited by 84

See all cited by

- Version 1